Support For Adjunctive Vitamin C Treatment In Cancer
ScienceDaily (Mar. 5, 2009) — Serious flaws in a recent study, which concluded that high doses of vitamin C reduce the effectiveness of chemotherapeutic drugs in the treatment of cancer, are revealed in the current issue of Alternative and Complementary Therapies, a journal published by Mary Ann Liebert, Inc.
In the Medical Journal Watch column of the latest issue, Jack Challem, a personal nutrition coach and nutrition author from Tucson, Arizona, and a regular contributor to the Journal, challenges the findings of a study published in Cancer Research (2008;68:8031-8038), in which the authors conclude that vitamin C given to mice or cultured cells treated with common anti-cancer drugs reduces the antitumor effects of the chemotherapeutic agents.
Challem points out two main problems with the study: the oxidized form of vitamin C (dehydroascorbic acid) and not actual vitamin C (ascorbic acid) was used; and in the mouse experiments, the animals were given toxic doses of dehydroascorbic acid, a compound that is not used as a dietary supplement in humans.
"This study and the subsequent headlines were a grievous disservice to physicians and patients with cancer," says Challem. He adds that "considerable positive research…has shown striking benefits from high-dose vitamin C (ascorbic acid) in cancer cells and animals—and in actual human beings."
High-dose intravenous vitamin C is a common form of alternative and complementary therapy for patients receiving chemotherapeutic drugs and is believed to help bring about tumor cell death. In addition, it may promote postsurgical healing by enhancing collagen formation, and increase tissue resistance to tumor spread.
Challem suggests that, "The ideal therapeutic approach would be to tailor individual treatment, including IV vitamin C, from a menu of options."
翻译软件翻译：
支持对维生素C的辅助治疗癌症
ScienceDaily（2009年3月5日） -在最近的研究，得出结论说，高剂量的维生素C减少在治疗癌症的化疗药物的有效性严重的缺陷，揭示在替代和辅助疗法，一杂志最新一期发表玛丽安博特公司
在医学杂志观看最新一期，杰克Challem，个人营养教练和营养的图森，亚利桑那和经常为华尔街日报撰文列，挑战癌症研究（2008年公布的一项研究的结果; 68:8031 -8038），其中，作者总结，维生素C给小鼠或培养细胞治疗具有共同的反抗癌药物降低了化疗药物的抗肿瘤作用。
出两个主要问题的研究：维生素氧化表C（抗坏血酸），而不是实际的维生素C（抗坏血酸）Challem点用，并在小鼠实验中，动物被赋予了脱氢抗坏血酸，这种化合物中毒剂量这不是作为人类膳食补充剂。
“这项研究及其后的标题[它产生]是一个严重伤害了医生和癌症患者说：”Challem。他补充说：“相当大的积极的研究...显示惊人的受益于高剂量的维生素C（抗坏血酸）在肿瘤细胞和动物，并在实际的人。”
大剂量静脉注射维生素C是一种替代和补充接受化疗药物的患者的治疗常见的形式，被认为是帮助实现肿瘤细胞死亡。此外，它可以促进胶原蛋白的形成，增强手术后愈合，增加组织抗肿瘤扩散。
Challem表明，“理想的治疗方法是个性化的个人待遇，包括四，维生素C从选项菜单。”
小细胞肺癌患者接受口服化疗合并高剂量维他命C静脉注射之个案报告
林淑娟(Shu-Chuan Lin) ; 陈明丰(Ming-Feng Chen)秀传医学杂志
小细胞肺癌为转移性高的恶性肿瘤，其治疗以静脉注射组合抗癌化学药物为主，其中又以静脉注射VP-16(etoposide)合并cisplatin最为常用。对于无法接受静脉注射化学治疗的高龄小细胞肺癌患者而言，如何控制肿瘤的快速成长及转移常是令临床医师头痛的问题。本文将介绍一个因接受传统静脉注射化学药物、VP- 16(etoposide)合并cisplatin导致严重副作用的83岁广范性小细胞肺癌患者。他于改为接受口服etoposide（每日150 mg连续3周，停1周）合并每周静脉注射高剂量维他命C (50g-60g)四个月后，肿瘤获得完全缓解，且未出现明显副作用。患者虽于终止口服etoposise五个月后因肿瘤复发而死亡，但在肿瘤复发前生活机能一直维持在良好状态，而且其存活期（10个月）仍长于一般单独接受口服 etoposide之广泛性小细胞肺癌患者的中位存活期（约4.8个月）。此结果显示，维他命C或许可以加强口服Etoposide的抗癌作用。至于维他命C如何加强化学药物的抗癌作用值得更进一步探讨。
[ 本帖最后由 ygswb 于 2009-9-2 11:13 编辑 ]
Originally published in February 2003 icon
Alternatives to Chemotherapy ~ Are there safer ways of killing cancer cells?
Are There Safer Ways of Killing Cancer Cells?
Conventional oncology largely uses chemotherapy to destroy cancer cells.
There can be no doubt that chemotherapy works, and that in every cancer case, cancer cells need destroying.
Chemotherapy is backed by high quality clinical trials and has been studied extensively for nearly 40 years.
Practically every known solid tumour has a solid evidence base and the oncologist will be able to give you a pretty accurate percentage success rate for any particular treatment regime, in any particular solid cancer. However, clearly, chemotherapy has a downside as it is a highly toxic treatment and in many patients is poorly tolerated. There are studies in conventional oncology literature implying that a significant number of patients can die of chemotherapy, as opposed to the cancer.
A play on BBC2, called WIT, enacted a harrowing story about an English Professor dying of cancer. The heroine was brilliantly acted by Emma Thompson. The dramatic high point came when the heroine said to camera:
"It's not the Cancer that's killing me; It's the treatment""
"Everyone in medicine understands that a great deal of uncertainty about what to do for people, will always remain in any illness. Human disease and lives are too complicated for reality to be otherwise". This is taken from a recent book by Atul Gawande entitled "Complications: A Surgeon's Notes on an Imperfect Science".
Cancer is just such a complex illness. Current medicine is evidence based as outlined earlier in this article. However, what happens if you do not wish to have a conventional treatment such as chemotherapy? Are there alternatives? Yes, there are, but they currently have a poor evidence base, and are never likely to have the quality of evidence base which backs chemotherapy. Providing the cancer sufferer knows what the evidence is, then they can make treatment choices on an informed consent basis. In my view, it's unethical for patients to be offered any treatment with a less good evidence base than chemotherapy, other than on an informed consent basis.
High dose intravenous vitamin C is one of these treatments, and we use it extensively in our clinic. It is one of our most effective treatments.
Clearly, because of the poor evidence base, we largely see chemotherapy and radiotherapy failures, but interestingly enough, those patients who deliberately seek us out and wish to try these approaches as a first line option, tend to be the "more well informed" public, and these include some doctors, which is indeed a curious situation.
Vitamin C (ascorbic acid) is a major water-soluble antioxidant with a variety of biological functions. It may be important in maintaining proper immune cell function. Even though vitamin C commonly functions as an antioxidant, it can also act as a pro-oxidant, that is actually oxidising tissues, which is what chemotherapy does.
Vitamin C converts free radicals into hydrogen peroxide, a molecule that can damage cell membranes if not neutralised by an enzyme inside the cell called catalase.
Tumour cells have 10-1 00 times less catalase than normal cells, and are therefore more sensitive than normal to hydrogen peroxide. Vitamin C accumulates in solid tumours at concentrations higher than those in surrounding normal tissue. The accumulation of vitamin C preferentially in cancer tissues has raised concerns that vitamin C may provide tumours with anti-oxidant protection from chemotherapeutic agents. In practice therefore, the avoidance of vitamin C and indeed all antioxidants, when going through a chemotherapy programme, is important.
To obtain vitamin C at pro-oxidant levels, at which it destroys cancer cells, is only achievable by intravenous infusion.
Plasma levels of vitamin C between 300-400 milligrams per 100cc are required in order to kill significant numbers of cancer cells. This requires intravenous infusions of 75 grams of vitamin C, (in some cases less, depending on the size of the patient and the tumour cell mass), infused intravenously on a daily basis for three weeks in order to be able to attain these plasma levels. It's important to realise that the highest plasma level of vitamin C achievable in humans using oral supplementation is 4.5 milligrams per 100cc.
Many studies have been done on this approach in the laboratory and Phase I and Phase II clinical trials have been completed on this approach. (Phase II clinical trials have been carried out in Nebraska, USA and are about to be published). Phase III clinical studies are in discussion.
Our most common protocol is the use of 75 grams of vitamin C, in sterile water, with a number of minerals, particularly magnesium, zinc, chromium, selenium, B12 and some B vitamins.
The patient is infused over 2.5 hours daily for 3 weeks (excluding weekends). The vitamin C level at the end of the infusion course is tested and if this is sufficiently high then some significant tumour kill has happened. If it isn't, then this regime may have to be repeated.
The advantage of using this approach is that it doesn't carry the downsides of chemotherapy, and can be repeated many times.
The main downside is that if we are working with patients who have fluid accumulation in the chest, say from a lung cancer, or in the abdomen, say from ovarian cancer, then the fluid load that these intravenous infusions involve can make the situation worse. So in those patients we choose other safe options to kill cancer cells.
Concurrently with the high dose intravenous vitamin C, we use supplements, the most important of which is lipoic acid.
Lipoic acid has been found to enhance the cancer killing effect of vitamin C, and the mechanism for this is unknown.
The only side effect we see in this treatment is tiredness due to tumour cell death, as well as increased fluid accumulation in particular groups of patients, as mentioned above.
So in conclusion, even though chemotherapy has such a high quality evidence base, it doesn't mean that other, less well-researched treatments do not also work.
Dr Julian Kenyon
Dr Julian Kenyon (Medical Director)
The Dove Clinic for Integrated Medicine, London & Winchester.
Dr Julian Kenyon started life as an academic surgeon then, soon after the cultural revolution, went to China, having been fascinated by traditional Chinese medicine.
On his return he founded the British Medical Acupuncture Society.
He is founder president of the British Society of Integrated Medicine and Medical Director of the Dove Clinic of Integrated Medicine, London and Winchester.
His main clinical interests are complex illnesses, particularly chronic fatigue syndrome, and cancer.
翻译软件翻译：
最初发表于2003年2月图标
替代化疗〜是否有杀死癌细胞的更安全的方式？
是否有杀死癌细胞的更安全的方式？
主要是利用常规肿瘤化疗摧毁癌细胞。
不可能有任何疑问，化疗的作品，并在每一个癌症的情况下，需要摧毁癌细胞。
化疗是支持高品质的临床试验和研究了近40年广泛。
几乎所有的已知实体瘤具有坚实的证据基础和肿瘤学家可以给你一个非常准确率为任何特定的治疗方案的成功率在任何特定实体癌。但是，显然，化疗有一个缺点，因为它是一种剧毒的待遇，而且在许多病人的耐受性很差。有文学传统肿瘤研究暗示，一个相当多的患者可以死于化疗，而不是癌症。
关于BBC2发挥，呼吁改善小组，制定了有关的英语教授，死于癌症的悲惨故事。出色的女主人公是采取行动埃玛汤普森。高点的急剧正值女主人公说相机：
“这不是癌症的杀死我，这是治疗”“
“在医学上每个人都明白，在做什么人们很大的不确定性，将永远留在任何疾病。人类疾病和生命太复杂的现实，否则将”。这是由一个由Atul Gawande最近出版的题为“并发症：一个外科医生的债券在非理想的科学”。
癌症是这样一个复杂的疾病。目前的医学证据显示，在所列本文前面的基础。然而，会发生什么，如果你不希望有这样一个传统的化疗治疗？是否有办法？是的，有，但他们目前的证据基础差，并且永不可能有证据的基础，支撑化疗质量。癌症患者提供了知道什么证据，那么他们可以在知情同意的基础治疗选择。我认为，这是不道德的患者提供了比化疗不太好的证据的基础，除了在知情同意的基础上其他任何治疗。
大剂量静脉注射维生素C是这些治疗手段之一，并利用它在我们的临床广泛。这是我们最有效的治疗手段之一。
显然，由于恶劣的证据基础，我们主要看到化疗和放疗的失败，但有趣的是，谁的病人刻意要我们出去，并希望尝试，作为第一线选择这些办法，往往是“更充分了解”公共，这些包括一些医生，这确实是一个奇怪的局面。
维生素C（抗坏血酸）是一个重要的水生物具有多种功能的水溶性抗氧化剂。这可能是重要的免疫细胞维持正常功能。尽管维生素C，经常作为一种抗氧化剂的功能，它也可以作为亲氧化剂，这实际上是氧化性组织，这正是化疗一样。
维生素C转化为过氧化氢的分子，能够破坏细胞膜，如果不是由细胞内的过氧化氢酶的瓦解称为自由基。
肿瘤细胞具有10月1日00倍不到正常细胞过氧化氢酶，因此超过正常的过氧化氢敏感。维生素C积累的浓度高于周围正常组织为高，在实体肿瘤。维生素C的优先在癌组织中，已引起关注，维生素C可以提供抗肿瘤，化疗药物的氧化剂，从保护的积累。因此，在实践中的维生素C和实际上所有的抗氧化剂，避免外出时通过一个化疗方案，是重要的。
要获取维生素的亲氧化剂水平荤，它在摧毁癌细胞，只有通过静脉滴注实现。
血浆维生素C水平之间的300-400毫克每100cc需要以杀死癌细胞的大量。这需要75克维生素C静脉注射，（在某些情况下减少，根据病人的规模和质量的肿瘤细胞），注入每天静脉注射3周，以便能够实现这些血浆。重要的是要意识到，维生素C在人类实现使用口服补充是4.5毫克每100cc最高血浆水平。
许多研究已经做了这个在实验室和一期和二期临床试验的方法已在这个方法完成。 （第二期临床试验已经进行了内布拉斯加州，美国和即将出版）。第三阶段临床研究进行讨论。
我们最常见的协议是75克的维生素C使用，无菌水，与一些矿物质，尤其是镁，锌，铬，硒，维生素B12和一些维生素B。
注入病人是每天2.5小时以上为3周（不包括周末）。在维生素C在输液课程结束时的水平进行测试，如果这是相当高，然后杀死一些重大的肿瘤发生。如果不是，那么这一制度可能要重复。
使用这种方法的优点是它不进行化疗的缺点，而且可以重复多次。
主要缺点是，如果我们是与病人谁的胸部有积水的工作，从肺癌，或在腹部说，说从卵巢癌，那么这些液体负荷涉及静脉注射可以使情况变得更糟。因此，在这些患者，我们选择其他安全选项以杀死癌细胞。
与高剂量静脉注射维生素C的同时，我们使用的补充，其中最重要的是硫辛酸。
硫辛酸已经发现，以提高癌症死亡的维生素C的效果，而且因为这是未知的机制。
唯一的副作用，我们看到了这种治疗方法是由于疲劳肿瘤细胞死亡，并增加患者特定群体积水，如上所述。
总括而言，尽管化疗有如此高品质的证据基础，但这并不意味着其他，不注重研究的治疗方法不同时工作。
凯尼恩朱利安博士
朱利安博士凯尼恩（医务总监）
对于中西医结合，伦敦和温彻斯特鸽诊所。
凯尼恩开始朱利安博士作为学术外科医生当时的生活后不久，文化革命，到中国后，被中医着迷。
他返回，他创立了英国医学针灸学会。
他创办的综合医学和医学鸽中西医结合主任，伦敦和英国的温切斯特诊所学会会长。
他的主要临床利益的复杂疾病，特别是慢性疲劳综合症和癌症。
Cancer and Vitamin C What are the facts?
By Dr Julian Kenyon
The use of vitamin C in cancer is highly controversial. There is evidence that vitamin C is preferentially toxic to cancer cells starting with research published in 1969 and several papers since.
The theory behind the toxicity of vitamin C is due to the relative deficiency of catalase in tumour cells. Catalase is an important enzyme present in every cell in the body. Catalase in cancer cells occurs at ten to a hundred times less concentration than in normal cells.
Looking at the specific metabolism of cancer cells and targeting the vulnerable aspects of cancer cell metabolism is becoming increasingly popular and has been the subject of several papers. For example inhibiting the protease and collagenase enzymes produced by cancer cells can be very helpful and a number of constituents in fermented soya products can do this. These particular enzymes are produced by cancer cells in order to dissolve surrounding tissue so the cancers can increase in size and travel around the body in order to form secondary growths.
Some studies have shown that people with high circulating volumes of vitamin C have lower cancer incidence. This is noted epidemiologically in populations who eat large amounts of fruit, the best example are the Costa Ricans. However, it is not at all sure that the situation is the same when you have got cancer as to when you haven't got cancer. Our work is indicating to us, in some cases, that the use of antioxidants such as vitamin C and indeed vitamin A and vitamin E might not be helpful if you actually have cancer, because the cancer cells may use these antioxidants as protection for themselves and may make the patient worse. A study published in the New England Journal of Medicine in 1994, looked at the effects of carotenes (vitamin A preparations), to see whether they would be helpful in preventing cancer, the study yielded unexpected results. Two major intervention studies were carried out with beta carotene, one in Finland among smokers and the other in the United States among people who had been exposed to asbestos. Smokers have a higher incidence of lung cancer than non-smokers, people exposed to asbestos have a higher incidence of mesothelioma of the pleura, which is a cancer of the covering membrane of the lungs, than people who have not been exposed. More people receiving the supposedly protective supplements died from cancers of the lung, pleura and other cancers, than people receiving a non-active medication (a placebo). It was considered at the time that these studies had faulty design. I have looked at them in detail and I do not think that is the case. I think the probability is that amongst the people on the trial who had been exposed to asbestos and who were smokers, there would have been a significant number with very very small cancers, either lung cancers or mesothelioma of the pleura which were asymptomatic. The use of antioxidant vitamins (in this case beta carotene, which is essentially a vitamin A derivative), 'fed' the cancer and produced the higher death rate amongst the study group. The number of patients dying in this study wasn't high, but it was a significant number. I am unable to see any design flaws in these studies.
So, how does this apply to vitamin C and vitamin E in cancer? The studies are all very confused on this issue, but my feeling is that the use of any antioxidant vitamins when a patient has got cancer, means that the cancer cells may use those antioxidant vitamins in order to feed the cancer. This is by no means proven, and I am well aware that this a controversial statement, but I think it is an important question to ask.
What about using vitamin C as a pro-oxidant instead of an antioxidant? In this situation one would have to use very high doses of vitamin C. It is not possible to use vitamin C as a pro-oxidant when taking it by mouth, as the maximum concentration in the serum which one can achieve by oral supplementation is 5 mg per 100 cc's. In order to achieve pro-oxidant levels, one needs to have serum levels of at least 50 mg per 100 cc's. This has to be achieved by giving the vitamin C intravenously. The effect of the use of vitamin C as a pro-oxidant is to oxidise the cancer cells, and that is the same mechanism as many chemotherapy drugs use. The advantage that high dose intravenous vitamin C has is that it does not carry the down sides of chemotherapy. There are several papers, including one in the British Journal of Cancer showing that vitamin C used at pro-oxidant levels is effective in killing cancer cells, so it is possible to use high dose intravenous vitamin C as a chemo-therapeutic agent. We use this approach regularly in our clinic, and we measure serum levels of vitamin C following courses of vitamin C used at these levels. Generally speaking the more tumour load there is, the more courses of high dose intravenous vitamin C we have to use. The standard is for us to use a three week course of high dose intravenous vitamin C. This is one of our most successful approaches to the treatment of cancer.
Several studies are being carried out in the United States, to look further at the use of intravenous vitamin C as a cancer killing agent.
So where does that leave the man in the street? If you have not got cancer then the use of anti-oxidants is a good idea.
If you have got cancer, then this is a completely different ball game, and you may have to think carefully and get informed advice on this. Unfortunately informed advice assumes that it is a good thing to take anti-oxidants if you have got cancer. I would suggest that this may not always be the case.
翻译软件翻译：
癌症和维生素C的事实是什么？
凯尼恩朱利安博士
维生素C的癌症是高度争议。有证据表明，维生素C是优先毒性癌细胞在1969年发表的研究论文和一些自启动。
背后的维生素C是由于过氧化氢酶在肿瘤细胞毒性理论相对不足。过氧化氢酶是一种重要的每个体细胞酶的存在。在肿瘤细胞中过氧化氢酶发生在10至100倍，不到正常细胞的浓度。
回顾癌细胞的代谢和针对特定癌症细胞的新陈代谢方面的弱势日益普及，并已在几个文件的主题。例如抑制蛋白酶和胶原酶癌细胞产生的酶可以是非常有益的成分，并在发酵大豆产品的数量可以做到这一点。这些特殊的酶产生的癌细胞，以溶解周围组织，因此可以增加癌症的大小和身体周围的旅行，以便形成二次生长。
一些研究表明，高循环量的维生素C的人癌症发病率较低。这是人群中指出，谁吃大量的水果，最好的例子流行病学是哥斯达黎加人。但是，它肯定不是在所有的情况是当你已经掌握了当你有没有患癌症癌症一样。我们的工作是对我们表示，在某些情况下，抗氧化剂，如维生素C和维生素A确实和维生素E也许没有帮助，如果你确实有癌症的，因为癌细胞可能会使用作为保护自己和这些抗氧化剂可能使病人恶化。在新英格兰医学杂志在1994年的一项研究，在胡萝卜素的影响研究（维生素A制剂），看看他们是否会在预防癌症有帮助的，这项研究取得了意想不到的结果。两个主要的干预研究，进行了β-胡萝卜素，其中一个吸烟者，在美国，芬兰等谁曾在接触石棉的人。吸烟者的肺癌超过癌症发生率较高的非吸烟者，接触石棉的人有一个胸膜，这是对肺部覆盖膜癌，比人们谁没有接触间皮瘤发病率更高。更多的人理应得到保护的补充死于肺癌，胸膜癌和其他癌症，比人接受非活性药物（安慰剂）。据认为，在当时，这些研究的设计有缺陷。我已经看过他们在详细研究，我不认为如此。我认为可能性就是，在对谁曾接触石棉，谁的烟民审判的人，就不会有非常非常小的癌症有相当数量的，无论是肺癌或胸膜间皮瘤这些病征。抗氧化维生素的使用（在这种情况下β-胡萝卜素，它在本质上是维生素A的衍生物），'喂'癌症和产生的研究组之一，死亡率较高。在这份研究死亡的病人数目不高，但它是一个相当数量。我无法看到这些研究设计上的缺陷。
那么，如何这是否适用于维生素C和维生素E在癌症？这些研究都非常混乱对这个问题，但我的感觉是，任何使用抗氧化维生素时，针对病人得了癌症，意味着癌细胞可能会使用这些抗氧化维生素，以饲料癌症。这绝不是证明，我深知这是一个有争议的声明，但我认为这是一个重要问题要问。
怎么样用亲氧化剂，而不是抗氧化剂维生素C？在这种情况下人们就不得不使用维生素C非常高剂量是不可能用作亲氧化剂时服用维生素C的口中，作为其中一个的血清能达到口服补充最高浓度为5毫克每100毫升的。为了实现亲氧化剂的水平，人们需要有至少50每100毫升的血清毫克。这必须通过给予维生素 C静脉实现。对维生素C的亲氧化剂的使用效果是氧化后，癌细胞，而这正是许多化疗药物的使用同样的机制。它的优点是大剂量静脉注射维生素C的是它不进行化疗的下降方面。有几个文件，包括在英国癌症杂志1显示，维生素C在亲氧化剂的水平是比较有效的杀死癌细胞，因此有可能以此作为化疗治疗剂大剂量静脉注射维生素C。我们经常使用这种方法，在我们的诊所，我们测量血清中维生素C以下这些层面使用了维生素C的课程。一般来说，越有肿瘤负荷，高剂量静脉注射维生素 C的更多课程，我们必须使用。该标准是对我们使用大剂量静脉注射维生素C，这三个星期的课程是我们最成功的方法治疗癌症之一。
几项研究正在进行中的美国，看的维生素C注射剂作为杀死癌细胞的进一步。
那么，是留在街上的人吗？如果您有没有患癌症，然后使用反氧化剂是一个好主意。
如果您遇到癌症，那么这是一个完全不同的球的游戏，您可能必须仔细考虑并得到有关这一意见。不幸的是信息咨询假定它是一件好事，采取反如果您有得癌症氧化剂。我认为这未必总是如此。
不知道最近有没有新的研究进展，版主是否指点一下？
这么次毛的翻译软件不用也罢
本帖最后由 jaydad 于 2014-1-5 13:47 编辑
讨论这个主题, 你必须了解这两位先人, 一是 LINUS PAULING, 莱纳斯·鲍林, 就是化学课本上的"保林", 美国著名化学家, 曾获1954年诺贝尔化学奖和1962年诺贝尔和平奖; 另一位是 ABRAM HOFFER, 加拿大精神病科医生和维生素专家.
HOFFER 早在六十年代治疗精神病人时,偶然发现注射大剂量维C和维B3(也叫烟酸), 不仅在预料中把病人从神经错乱中解救出来, 还竟然出乎意料把一位同时患末期肺癌的病人的癌症给治消失了.后来在他的长期医疗实践中(是的他改做肿瘤科了)他经历过更多的(各种)癌症被静注高剂量维C控制甚至治愈的病例.七十年代末开始, 他一共记载了 134 位癌症病人的维C治疗数据, 发现治疗组和对照组的生存时间有显著的区别.因为他是自发做的研究, 并未获得官方认可. 他死前把一生心得写成总结, "Clinical Procedures in Treating Terminally Ill Cancer Patients with Vitamin C (用维C治疗末期癌症病人的临床体会)". 得到许多替代治疗网站的转载. 譬如, http://www.whale.to/a/hoffer1991.html
保林先生的后期生涯中致力于维C和健康研究, 并成立莱纳斯·保林研究所. 他也是HOFFER医生临床研究的鼎力支持者. 但他的研究遭遇了传统医学界大腕人物们的极端压杀, 其中 dingding 大名 MAYO CLINIC (梅奥诊所) 的 CHARLES MOERTEL 医生成了他的死敌. MOERTEL用政府资助的"正规"研究证明高剂量维C治疗癌症效果等同于安慰剂. 但维C治癌支持者和有良知的医界学界人士指出, 保林和HOFFER 医生倡导的是用 静 注/滴 高剂量维C, 而MOERTEL医生偏要避开用 静 注 办法给药.MOERTEL医生死前的另一个政治路线正确的研究成果是: "化疗和放疗治疗癌症有效".
病友们, 关于有争议的话题, 还是多听听各方意见吧. 我的偏见在这里有发过:
http://itisonlycancer.dxyer.cn/34460_79/
jaydad 发表于 2014-1-5 13:39
讨论这个主题, 你必须了解这两位先人, 一是 LINUS PAULING, 莱纳斯·鲍林, 就是化学课本上的"保林", 美国著 ...
2014-07-11
有条件的话, 我也会大量注射VC (每天 50克), 因为我知道这样做是无害的.有无益处有待事后或死后才见晓.但是搞不到针剂VC啊. 所以我每天只好吃 2 片VC, 每片 1 克 - [买的GNC vitamin c 1000 mg 片剂, 每瓶 500 片]